Role of computed tomography cardiac angiography in acute chest pain syndromes.


Journal

Heart (British Cardiac Society)
ISSN: 1468-201X
Titre abrégé: Heart
Pays: England
ID NLM: 9602087

Informations de publication

Date de publication:
24 08 2023
Historique:
received: 20 12 2022
accepted: 27 02 2023
medline: 28 8 2023
pubmed: 14 3 2023
entrez: 13 3 2023
Statut: epublish

Résumé

Use of CT coronary angiography (CTCA) to evaluate chest pain has rapidly increased over the recent years. While its utility in the diagnosis of coronary artery disease in stable chest pain syndromes is clear and is strongly endorsed by international guidelines, the role of CTCA in the acute setting is less certain. In the low-risk setting, CTCA has been shown to be accurate, safe and efficient but inherent low rates of adverse events in this population and the advent of high-sensitivity troponin testing have left little room for CTCA to show any short-term clinical benefit.In higher-risk populations, CTCA has potential to fulfil a gatekeeper role to invasive angiography. The high negative predictive value of CTCA is maintained while also identifying non-obstructive coronary disease and alternative diagnoses in the substantial group of patients presenting with chest pain who do not have type 1 myocardial infarction. For those with obstructive coronary disease, CTCA provides accurate assessment of stenosis severity, characterisation of high-risk plaque and findings associated with perivascular inflammation. This may allow more appropriate selection of patients to proceed to invasive management with no disadvantage in outcomes and can provide a more comprehensive risk stratification to guide both acute and long-term management than routine invasive angiography.

Identifiants

pubmed: 36914247
pii: heartjnl-2022-321360
doi: 10.1136/heartjnl-2022-321360
doi:

Types de publication

Journal Article Review Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1350-1356

Subventions

Organisme : British Heart Foundation
ID : RE/18/5/34216
Pays : United Kingdom
Organisme : British Heart Foundation
ID : RG/16/10/32375
Pays : United Kingdom
Organisme : British Heart Foundation
ID : FS/ICRF/20/26002
Pays : United Kingdom
Organisme : Wellcome Trust
ID : WT103782AIA
Pays : United Kingdom

Informations de copyright

© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: PDA, DEN and MCW are editorial board members of Heart.

Auteurs

Charlotte Greer (C)

Christchurch Heart Institute, University of Otago Christchurch, Christchurch, Canterbury, New Zealand.

Michelle C Williams (MC)

Centre for Cardiovascular Sciences, University of Edinburgh, Edinburgh, UK.

David E Newby (DE)

Centre for Cardiovascular Sciences, University of Edinburgh, Edinburgh, UK.

Philip D Adamson (PD)

Christchurch Heart Institute, University of Otago Christchurch, Christchurch, Canterbury, New Zealand Philip.adamson@cdhb.health.nz.
Centre for Cardiovascular Sciences, University of Edinburgh, Edinburgh, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH